Sepracor president told analysts that Lunesta share nearing 40%

Share this article:
Sepracor president William O'Shea told analysts and investors that Lunesta's share of the sleep-aid market is nearing 40%, thanks to the company's aggressive direct-to-patient promotional efforts. The firm will now initiate “Phase Two” of its Lunesta promotion by increasing sales capacity and rolling out its expanded clinical database for the drug, he said in the company's first-half earnings report. The firm reported six-month Lunesta revenues of $277 million.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.